-
1.发明申请Reconstituted histone methyltransferase complex and methods of identifying modulators thereof 失效重组组蛋白甲基转移酶复合物及其调节剂的鉴定方法公开(公告)号：US20050266473A1
公开(公告)日：2005-12-01
申请号：US11140659
申请日：2005-05-27
CPC分类号： C12N9/1007 , C07K14/82 , C07K2319/20 , C12N2799/026 , C12Y201/01043 , G01N2333/91011
摘要： The present invention provides a reconstituted complex including EED, EZH2 and SUZ12 wherein the reconstituted complex has histone methyltransferase (HMTase) activity for lysine 27 of histone H3 (H3-K27). The reconstituted complex may further include RbAp48, AEBP2 or both. Also disclosed are methods of producing the reconstituted complex, methods of identifying compounds that inhibit the HTMase activity of the reconstituted complex and methods of identifying candidate compounds for treating cancer. Reagents and kits including the reconstituted complex are further provided.
摘要翻译： 本发明提供了包含EED，EZH2和SUZ12的复原复合物，其中重构的复合物对组蛋白H3（H3-K27）的赖氨酸27具有组蛋白甲基转移酶（HMTase）活性。 重构的复合物还可以包括RbAp48，AEBP2或两者。 还公开了生产重建复合物的方法，鉴定抑制重构复合物的HTMase活性的化合物的方法和鉴定用于治疗癌症的候选化合物的方法。 还提供了试剂和试剂盒，包括重构的复合物。
-
2.发明授权Reconstituted histone methyltransferase complex and methods of identifying modulators thereof 失效重组组蛋白甲基转移酶复合物及其调节剂的鉴定方法公开(公告)号：US07563589B2
公开(公告)日：2009-07-21
申请号：US11140659
申请日：2005-05-27
CPC分类号： C12N9/1007 , C07K14/82 , C07K2319/20 , C12N2799/026 , C12Y201/01043 , G01N2333/91011
摘要： The present invention provides a reconstituted complex including EED, EZH2 and SUZ12 wherein the reconstituted complex has histone methyltransferase (HMTase) activity for lysine 27 of histone H3 (H3-K27). The reconstituted complex may further include RbAp48, AEBP2 or both. Also disclosed are methods of producing the reconstituted complex, methods of identifying compounds that inhibit the HTMase activity of the reconstituted complex and methods of identifying candidate compounds for treating cancer. Reagents and kits including the reconstituted complex are further provided.
摘要翻译： 本发明提供了包含EED，EZH2和SUZ12的复原复合物，其中重构的复合物对组蛋白H3（H3-K27）的赖氨酸27具有组蛋白甲基转移酶（HMTase）活性。 重构的复合物还可以包括RbAp48，AEBP2或两者。 还公开了生产重建复合物的方法，鉴定抑制重构复合物的HTMase活性的化合物的方法和鉴定用于治疗癌症的候选化合物的方法。 还提供了试剂和试剂盒，包括重构的复合物。
-
3.发明申请公开(公告)号：US20080248458A1
公开(公告)日：2008-10-09
申请号：US11915610
申请日：2006-06-01
申请人： Ru Cao , Hengbin Wang , Yi Zhang
发明人： Ru Cao , Hengbin Wang , Yi Zhang
CPC分类号： C12Q1/25 , C12N9/93 , G01N2333/9015 , G01N2500/02
摘要： The present invention provides a native or reconstituted complex comprising Bmi1 and/or Ring1 and/or Ring2, wherein the complex has ubiquitin E3 ligase activity. Optionally, the complex further comprises HPH2 and/or HPC3. Also disclosed are methods of producing the reconstituted complex, methods of identifying compounds that modulate the ubiquitin E3 ligase activity of the native or reconstituted complex, and methods of identifying candidate compounds for treating cancer. Kits for determining modulation of protein ubiquitination and/or for ubiquitinating a target substrate are further provided.
摘要翻译： 本发明提供了包含Bmi1和/或Ring1和/或Ring2的天然或重构的复合物，其中所述复合物具有泛素E3连接酶活性。 任选地，复合物还包含HPH 2和/或HPC 3。 还公开了产生重构复合物的方法，鉴定调节天然或重构复合物的泛素E3连接酶活性的化合物的方法以及鉴定用于治疗癌症的候选化合物的方法。 还提供了用于确定蛋白质泛素化和/或用于泛素化靶基质的调节的试剂盒。
-
4.发明申请RECONSTITUTED HISTONE METHYLTRANSFERASE COMPLEX AND METHODS OF IDENTIFYI NG MODULATORS THEREOF 审中-公开重组表达甲基转移酶复合物及其识别NG调节剂的方法公开(公告)号：US20090298105A1
公开(公告)日：2009-12-03
申请号：US12497211
申请日：2009-07-02
CPC分类号： C12N9/1007 , C07K14/82 , C07K2319/20 , C12N2799/026 , C12Y201/01043 , G01N2333/91011
摘要： The present invention provides a reconstituted complex including EED, EZH2 and SUZ12 wherein the reconstituted complex has histone methyltransferase (HMTase) activity for lysine 27 of histone H3 (H3-K27). The reconstituted complex may further include RbAp48, AEBP2 or both. Also disclosed are methods of producing the reconstituted complex, methods of identifying compounds that inhibit the HTMase activity of the reconstituted complex and methods of identifying candidate compounds for treating cancer. Reagents and kits including the reconstituted complex are further provided.
摘要翻译： 本发明提供了包含EED，EZH2和SUZ12的复原复合物，其中重构的复合物对组蛋白H3（H3-K27）的赖氨酸27具有组蛋白甲基转移酶（HMTase）活性。 重构的复合物还可以包括RbAp48，AEBP2或两者。 还公开了生产重建复合物的方法，鉴定抑制重构复合物的HTMase活性的化合物的方法和鉴定用于治疗癌症的候选化合物的方法。 还提供了试剂和试剂盒，包括重构的复合物。
-
公开(公告)号：US20050053682A1
公开(公告)日：2005-03-10
申请号：US10658194
申请日：2003-09-10
申请人： Yi Zhang , Yi Zhang , Qingjiang Wu
发明人： Yi Zhang , Yi Zhang , Qingjiang Wu
IPC分类号： A61K31/365 , A61K31/366 , A61K31/37 , A61K31/4741 , A61K36/75 , A61K35/78
CPC分类号： A61K36/75
摘要： Methods and uses pertaining to the oral treatment of anorectal conditions in a man or woman in need of such treatment are described, which comprises treatment with an orally effective amount of an extract of Cortex Dictamni in unit dosage form in association with one or more carriers or excipients.
摘要翻译： 描述了与需要这种治疗的男性或女性口腔治疗肛门直肠病症有关的方法和用途，其包括以口服有效量的单位剂量形式的皮质硬脑膜炎提取物与一种或多种载体或 赋形剂。
-
公开(公告)号：US20230138190A1
公开(公告)日：2023-05-04
申请号：US18091673
申请日：2022-12-30
申请人： Yi Zhang , Maruti Gupta Hyde , Ziyi LI , Vaibhav Singh , Christian Maciocco , Jaemin Han
发明人： Yi Zhang , Maruti Gupta Hyde , Ziyi LI , Vaibhav Singh , Christian Maciocco , Jaemin Han
摘要： An apparatus and system of providing energy saving in a network are described. A target node receives, from a source node, a handover request to handover a UE due to at least one of entry of the source node into a power saving state or mobility optimization. In response, the target node transmits a relative energy efficiency value of Bits per Joule and periodic feedback related to a status of the UE for training an AI/ML energy saving model and stops the feedback in response to a stop parameter being met. The stop parameter is a first of: a predicted period of the source node to stay in the power saving state or time for a UE to connect to the target node, a percentage of UEs handed over that enter an idle or inactive state, and a percentage of UEs handed over that are further handed to another node.
-
公开(公告)号：US20230015807A1
公开(公告)日：2023-01-19
申请号：US17859542
申请日：2022-07-07
申请人： Yi Zhang
发明人： Yi Zhang
IPC分类号： A61N7/02
摘要： The present disclosure relates to transcranial ultrasound systems, devices, and methods which are used for treatment rather than for imaging or medical diagnosis. In accordance with one aspect, a system for applying ultrasound energy includes at least three ultrasound applicators configured to be secured against a head of a person and configured to apply ultrasound energy to the head of the person when activated, and a controller configured to control activation and deactivation of the at least three ultrasound applicators based on a predetermined treatment sequence.
-
-
公开(公告)号：US11124527B2
公开(公告)日：2021-09-21
申请号：US15579830
申请日：2016-06-03
申请人： Syros Pharmaceuticals, Inc. , Christopher Roberts , Yi Zhang , Francis Beaumier , Luce Lépissier
发明人： Jason J. Marineau , Peter B. Rahl , Kevin Sprott , Stephane Ciblat , Boubacar Sow , Robin Larouche-Gauthier , Lauren Berstler , Christopher Roberts , Yi Zhang , Francis Beaumier , Luce Lépissier
IPC分类号： C07D513/04 , A61P35/00 , C07D495/04
摘要： The present invention provides novel compounds of Formulas (I) and (II) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases, e.g., cancers (e.g., breast cancer, prostate cancer, lymphoma, lung cancer, pancreatic cancer, ovarian cancer, neuroblastoma, or colorectal cancer), benign neoplasms, angio genesis, inflammatory diseases, fibrosis (e.g., polycystic kidney disease), autoinflammatory diseases, and autoimmune diseases in a subject.
-
公开(公告)号：US10893824B2
公开(公告)日：2021-01-19
申请号：US13306343
申请日：2011-11-29
摘要： A system and method for automatically analyzing heart failure in a patient, including collecting physiological data from a patient using at least a first sensor and a second sensor to collect two or more sensor measurements, and calculating a first composite value based on at least a first sensor measurement wherein the first composite value is an indication of a likelihood that the patient's heart failure status has changed. If the first composite value is outside of a first specified range, then a second composite value is calculated based on at least a second sensor measurement, wherein the second composite value is an indication of a likelihood that the patient's heart failure status has changed. If the second composite value is outside of a second specified range, then an alert of change in heart failure status is generated.
-
-
-
-
-
-
-
-
-
搜索结果
546 条记录 (耗时 0.027 秒)
